Michael Saag | Academic Influence

Michael Saag's AcademicInfluence.com Rankings

Michael Saag

Philosophy

#4938

World Rank

#7622

Historical Rank

#1361

USA Rank

Logic

#2423

World Rank

#3413

Historical Rank

#581

USA Rank

philosophy Degrees

Download Badge

Philosophy

Michael Saag's Degrees

Doctorate Medicine University of Louisville
Bachelors Biology University of Louisville

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Michael Saag Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michael S. Saag is a physician and prominent HIV/AIDS researcher at the University of Alabama at Birmingham . He holds the Jim Straley Chair in AIDS Research, is Director of the Division of Infectious Disease and of the William C. Gorgas Center for Geographic Medicine, and Director of the Center for AIDS Research. He is also the founder of the 1917 Clinic, a comprehensive AIDS treatment and research center at UAB Saag is a frequent lecturer at AIDS conferences around the world and is credited with performing pioneering clinical trials for several antiretroviral drugs now in common use for HIV treatment and for first demonstrating the clinical value of "viral-load testing" in HIV/AIDS treatment. In 2009 Saag was elected chairman of the HIV Medicine Association of the Infectious Diseases Society of America. In 2019 Saag began serving on the Presidential Advisory Council on HIV/AIDS.

(See a Problem?)

Michael Saag's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Viral dynamics in human immunodeficiency virus type 1 infection (1995) (2904)
Antibody neutralization and escape by HIV-1 (2003) (2464)
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection (2008) (1911)
Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy (2002) (1573)
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. (1993) (1327)
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. (1997) (1316)
Effect of early versus deferred antiretroviral therapy for HIV on survival. (2009) (1170)
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. (2000) (1117)
The Sanford guide to antimicrobial therapy (2010) (1061)
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. (2000) (1044)
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry (1998) (1011)
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. (1998) (1006)
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies (2009) (806)
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection (2009) (781)
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. (2002) (777)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. (2006) (769)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. (2016) (753)
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. (1997) (735)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. (2004) (730)
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. (1991) (726)
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. (2006) (725)
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies (2017) (691)
Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV (1994) (680)
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel (1996) (651)
Treatment for adult HIV infection. (2004) (580)
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. (2010) (577)
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. (1992) (576)
HIV viral load markers in clinical practice (1996) (561)
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (2015) (529)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel (2018) (527)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 (2005) (505)
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. (1995) (477)
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. (2012) (475)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. (2015) (459)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. (1996) (451)
Azole antifungal agents: emphasis on new triazoles (1988) (450)
Missed visits and mortality among patients establishing initial outpatient HIV treatment. (2009) (441)
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. (2014) (435)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study (2014) (426)
Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV‐1 Infection: Recommendations of an International AIDS Society‐USA Panel (2002) (419)
Extensive variation of human immunodeficiency virus type-1 in vivo (1988) (418)
Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis (2000) (398)
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial (2011) (398)
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. (2007) (386)
The therapeutic implications of timely linkage and early retention in HIV care. (2009) (375)
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. (2008) (373)
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. (1999) (364)
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. (2008) (353)
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. (1992) (322)
Antigenic conservation and immunogenicity of the HIV coreceptor binding site (2005) (316)
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. (2009) (306)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. (2015) (288)
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. (2004) (283)
Biologically diverse molecular variants within a single HIV-1 isolate (1988) (282)
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. (2010) (278)
Anemia in HIV infection: clinical impact and evidence-based management strategies. (2004) (262)
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. (1998) (252)
Itraconazole therapy for blastomycosis and histoplasmosis (1992) (247)
Fat Distribution in Men With HIV Infection (2005) (246)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. (2020) (246)
Determinants of Human Immunodeficiency Virus Type 1 Escape from the Primary CD8+ Cytotoxic T Lymphocyte Response (2004) (243)
A Randomized Controlled Trial to Reduce HIV Transmission Risk Behaviors and Sexually Transmitted Diseases Among Women Living With HIV: The WiLLOW Program (2004) (236)
Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. (2011) (226)
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. (2008) (224)
Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA (1999) (220)
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK (2013) (219)
Late presentation for human immunodeficiency virus care in the United States and Canada. (2010) (215)
Early Retention in HIV Care and Viral Load Suppression: Implications for a Test and Treat Approach to HIV Prevention (2012) (210)
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. (1999) (207)
Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. (2000) (202)
Predictors of optimal virological response to potent antiretroviral therapy. (1999) (202)
Aging With HIV: A Cross‐Sectional Study of Comorbidity Prevalence and Clinical Characteristics Across Decades of Life (2011) (200)
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. (2009) (200)
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. (2002) (194)
Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study (2013) (193)
Prevention of Relapse of Histoplasmosis with Itraconazole in Patients with the Acquired Immunodeficiency Syndrome (1993) (183)
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). (2007) (178)
Modeling sequence evolution in acute HIV-1 infection. (2009) (175)
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. (2011) (170)
Racial Disparities in HIV Virologic Failure: Do Missed Visits Matter? (2009) (170)
Distribution of health care expenditures for HIV-infected patients. (2006) (167)
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials (2012) (165)
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. (2004) (164)
A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase (1993) (151)
Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. (1994) (147)
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study (2015) (146)
Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. (1996) (143)
Multimorbidity Patterns in HIV-Infected Patients: The Role of Obesity in Chronic Disease Clustering (2012) (142)
Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. (2014) (140)
Evaluation of the Single-Item Self-Rating Adherence Scale for Use in Routine Clinical Care of People Living with HIV (2012) (140)
Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections (2011) (139)
Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. (1997) (138)
Failure to establish HIV care: characterizing the "no show" phenomenon. (2007) (135)
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. (2009) (134)
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. (2011) (134)
Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. (2001) (134)
Health-related Quality of Life and Virologic outcomes in an HIV Clinic (2004) (131)
Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. (1993) (131)
HIV Infection and Obesity: Where Did All the Wasting Go? (2012) (128)
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia (2008) (127)
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy (2008) (126)
High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels. (1991) (126)
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. (1995) (125)
HIV Discrimination and the Health of Women Living with HIV (2007) (123)
Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients (2014) (123)
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. (2004) (122)
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department (2015) (121)
Virologic and immunologic response to HAART, by age and regimen class (2010) (120)
Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjects (1995) (119)
Report of the NIH Panel To Define Principles of Therapy of HIV Infection* (1998) (117)
Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients With Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy (2008) (115)
Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States (2018) (115)
Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies (2014) (115)
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. (1998) (115)
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients (2007) (114)
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia (2009) (112)
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. (2013) (112)
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. (2008) (110)
Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy (2011) (110)
Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV‐infected patients (2010) (109)
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. (2009) (107)
Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients (2004) (103)
Pain, Mood, and Substance Abuse in HIV: Implications for Clinic Visit Utilization, Antiretroviral Therapy Adherence, and Virologic Failure (2012) (102)
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. (2010) (101)
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. (2008) (100)
Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems (2017) (99)
The effect of mode of administration on Medical Outcomes Study health ratings and EuroQol scores in AIDS (2004) (96)
Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population (2017) (94)
The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3 (2000) (91)
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. (2000) (91)
Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. (1999) (90)
HIV-specific cellular and humoral immune responses in primary HIV infection. (1996) (90)
Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. (2010) (89)
Duration of highly active antiretroviral therapy regimens. (2003) (89)
Viral dynamics in primary HIV-1 infection (1993) (88)
Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment (2017) (88)
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis (2000) (88)
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. (2010) (87)
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. (2006) (87)
Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing (2012) (87)
CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? (2010) (86)
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009 (2012) (86)
Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults (2000) (86)
Routine, self-administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting. (2010) (85)
Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults (2010) (85)
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV‐infected adults (1998) (85)
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. (2006) (84)
HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015 (2018) (84)
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy (2016) (84)
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. (2003) (83)
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care (2011) (83)
A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. (1993) (81)
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. (2008) (78)
Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy (2010) (75)
Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. (2012) (74)
Gastrointestinal complications of HIV infection: changing priorities in the HAART era (2008) (73)
Patient reported outcomes in routine care: advancing data capture for HIV cohort research. (2012) (72)
Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. (2006) (72)
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. (2009) (71)
Patient-perceived barriers to antiretroviral adherence: Associations with race (2002) (70)
Durability of Initial Antiretroviral Therapy in a Resource-Constrained Setting and the Potential Need for Zidovudine Weight-Based Dosing (2009) (70)
Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study (2010) (69)
Recurrence of the Acute HIV Syndrome after Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report (2000) (69)
Individuals infected with HIV possess antibodies against IL-2. (1988) (69)
Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). (2014) (68)
A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128 (2003) (68)
Gender Differences in Discontinuation of Antiretroviral Treatment Regimens (2009) (67)
Pain is independently associated with impaired physical function in HIV-infected patients. (2013) (65)
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. (1992) (64)
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. (2009) (64)
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus (2016) (62)
Measuring depression levels in HIV-infected patients as part of routine clinical care using the nine-item Patient Health Questionnaire (PHQ-9) (2010) (61)
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC) (2017) (61)
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC) (2017) (61)
Determination of plasma viral load in HIV‐1 infection by quantitative competitive polymerase chain reaction (1993) (60)
Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science. (2020) (60)
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511) (2001) (60)
Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America (2017) (59)
A Conceptual Framework for Understanding Chronic Pain in Patients with HIV (2014) (59)
Short-term discontinuation of HAART regimens more common in vulnerable patient populations. (2008) (58)
Enfuvirtide (2002) (56)
Migrating from a legacy fixed-format measure to CAT administration: calibrating the PHQ-9 to the PROMIS depression measures (2011) (56)
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis (2012) (56)
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? (2007) (55)
Types of Myocardial Infarction Among Human Immunodeficiency Virus–Infected Individuals in the United States (2017) (55)
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. (2011) (55)
HIV-1 and HAART: A time to cure, a time to kill (1999) (54)
Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. (1999) (53)
Use of HIV Viral Load in Clinical Practice: Back to the Future (1997) (48)
Asymptomatic blood donor with a false positive HTLV-III Western blot. (1986) (47)
Characteristics of an ambulatory palliative care clinic for HIV-infected patients. (2013) (47)
Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis (2016) (46)
HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. (2014) (46)
Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. (2006) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements (2009) (44)
HIV-1 sequence subtype D in the United States. (1994) (44)
Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 (2016) (43)
Access to Kidney Transplantation among HIV-Infected Waitlist Candidates. (2017) (41)
Routine Depression Screening in an HIV Clinic Cohort Identifies Patients with Complex Psychiatric Co-morbidities Who Show Significant Response to Treatment (2012) (41)
Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK (2012) (40)
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment (2016) (40)
Reanalysis of the MERIT Study with the Enhanced Trofile Assay (2008) (40)
How do HIV elite controllers do what they do? (2010) (40)
A pilot study of screening, brief intervention, and referral for treatment (SBIRT) in non-treatment seeking smokers with HIV. (2013) (40)
Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared. (1995) (39)
Ryan White: an unintentional home builder. (2009) (38)
Predictors of Nonseroconversion after SARS-CoV-2 Infection (2021) (38)
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration (2015) (38)
A 9-Point Risk Assessment for Patients Who Inject Drugs and Require Intravenous Antibiotics: Focusing Inpatient Resources on Patients at Greatest Risk of Ongoing Drug Use (2018) (38)
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. (2012) (37)
Sexually Transmitted Disease/HIV Transmission Risk Behaviors and Sexually Transmitted Disease Prevalence Among HIV-Positive Men Receiving Continuing Care (2005) (36)
The infectious etiology of chronic rheumatic diseases. (1987) (36)
Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. (2014) (36)
HIV primary care providers--Screening, knowledge, attitudes and behaviors related to alcohol interventions. (2016) (35)
Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia (2017) (35)
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. (2016) (35)
Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals. (1999) (34)
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings (2014) (34)
Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load (2011) (33)
Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study (2017) (33)
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption (2021) (33)
Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes (2018) (32)
Pain, Mood, and Substance Abuse in HIV: Implications for Clinic Visit Utilization, ART Adherence, and Virologic Failure (S701) (2013) (31)
Engagement in human immunodeficiency virus care: linkage, retention, and antiretroviral therapy adherence. (2014) (31)
Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation (2018) (31)
When to start antiretroviral therapy: as soon as possible (2013) (31)
Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-based Initial Antiretroviral Therapy Among Persons with HIV in the US and Canada. (2020) (31)
The Sanford Guide to HIV/AIDS Therapy (2000) (31)
Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline (2008) (30)
HIV protease inhibitor ritonavir induces lipoatrophy in male mice. (2003) (30)
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. (2001) (30)
Cigarette Smokers are Less Likely to Have Undetectable Viral Loads: Results From Four HIV Clinics (2016) (30)
Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. (2004) (29)
Antiretroviral prescribing patterns in treatment-naïve patients in the United States. (2010) (29)
The antiretroviral drug pipeline: prospects and implications for future treatment research (2013) (29)
Calmodulin antagonists inhibit apoptosis of CD4+ T-cells from patients with AIDS. (1998) (27)
Candidate antiretroviral agents for use in postexposure prophylaxis. (1997) (27)
Hit-and-Run Stimulation: a Novel Concept To Reactivate Latent HIV-1 Infection without Cytokine Gene Induction (2010) (27)
Factors Associated with Prescription of Opioids and Co-prescription of Sedating Medications in Individuals with HIV (2016) (27)
Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature. (2005) (27)
Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. (2015) (27)
Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy. (1999) (27)
Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss. (1997) (26)
Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. (1991) (26)
Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study (2011) (26)
Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. (2002) (26)
Physical Activity and Health Outcomes Among HIV-Infected Men Who Have Sex with Men: A Longitudinal Mediational Analysis (2013) (25)
Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic. (2010) (25)
Characterizing Failure to Establish Hepatitis C Care of Baby Boomers Diagnosed in the Emergency Department (2016) (25)
Decreased fat and nitrogen losses in patients with AIDS receiving medium-chain-triglyceride-enriched formula vs those receiving long-chain-triglyceride-containing formula. (1997) (25)
Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era. (2007) (25)
Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks. (2010) (24)
Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort (2014) (23)
Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men (2011) (23)
HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. (2009) (23)
Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients (2006) (23)
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir (2017) (23)
Treatment of histoplasmosis and blastomycosis. (1988) (22)
An Algorithm Approach to Determining Smoking Cessation Treatment for Persons Living With HIV/AIDS: Results of a Pilot Trial (2015) (22)
Impact of a computer-assisted, provider-delivered intervention on sexual risk behaviors in HIV-positive men who have sex with men (MSM) in a primary care setting. (2013) (22)
Issues in combination antiretroviral therapy: a review. (1994) (22)
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence (2014) (21)
Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure (2017) (21)
Cryptococcal meningitis in AIDS. (1993) (21)
Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection (2015) (21)
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? (2008) (20)
Diminished CD103 (αEβ7) Expression on Resident T Cells from the Female Genital Tract of HIV-Positive Women (2017) (20)
Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. (2006) (20)
Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic. (2008) (20)
New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings. (2012) (20)
‘Two Pains Together’: Patient Perspectives on Psychological Aspects of Chronic Pain while Living with HIV (2014) (20)
A Randomized Pilot Trial of a Novel Behavioral Intervention for Chronic Pain Tailored to Individuals with HIV (2018) (20)
Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care (2013) (19)
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. (2016) (19)
Aberrant drug-related behaviors: a qualitative analysis of medical record documentation in patients referred to an HIV/chronic pain clinic. (2014) (19)
Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. (2015) (19)
Antiretroviral chemotherapy. (1998) (19)
Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort (2018) (19)
A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics (2010) (18)
The Silent Epidemic - Frailty and Aging with HIV. (2016) (18)
High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR) (2007) (18)
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. (1997) (18)
Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS) (2019) (18)
HIV Infection - Screening, Diagnosis, and Treatment. (2021) (18)
Complete Blood Cell Count as a Surrogate CD4 Cell Marker for HIV Monitoring in Resource-Limited Settings (2007) (18)
Primary HIV-1 infection. (1991) (18)
Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV (2018) (18)
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. (1993) (18)
In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa (1986) (18)
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C–C motif) receptor 5 antagonists] (2009) (17)
Qualitative investigation of a Brief Chronic Pain Screening tool in HIV-infected patients. (2014) (17)
Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. (2010) (17)
Point-of-Care Urine Ethyl Glucuronide Testing to Detect Alcohol Use Among HIV-Hepatitis B Virus Coinfected Adults in Zambia (2018) (17)
Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. (2010) (17)
A Double-Blind , Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R 5 HIV-1 (2009) (16)
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy (2018) (16)
HIV now firmly established in the Middle Ages. (2011) (16)
Pathogenicity and diversity of HIV and implications for clinical management: a review. (1994) (16)
Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. (2006) (16)
Quantitative Evaluation of an Instrument to Identify Chronic Pain in HIV-Infected Individuals. (2015) (16)
Use of virologic markers in clinical practice. (1997) (15)
Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men who have Sex with Men and Men who have Sex with Women Engaged in Routine HIV Care in the United States (2018) (15)
Toward a definition of HIV expertise: a survey of experienced HIV physicians. (2001) (15)
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study (2016) (15)
Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. (2010) (15)
The impact of highly active antiretroviral therapy on HIV-specific immune function (2001) (15)
The role of palliative care in the current HIV treatment era in developed countries. (2013) (15)
Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain (2019) (15)
Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. (2001) (14)
Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study (2020) (14)
Preventing HIV in women--still trying to find their VOICE. (2015) (14)
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study (2009) (14)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. (2022) (14)
Temporal Trends in Presentation for Outpatient HIV Medical Care 2000–2010: Implications for Short-term Mortality (2011) (14)
Editorial Response: Clinical and Host Differences Between Infections with the Two Varieties of Cryptococcus neoformans (1995) (13)
Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. (2017) (13)
Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study (2012) (13)
Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus–Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study (2019) (13)
Associations of food insecurity and psychosocial measures with diet quality in adults aging with HIV (2019) (13)
Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? (1994) (13)
Using Patient Perspectives to Inform the Development of a Behavioral Intervention for Chronic Pain in Patients with HIV: A Qualitative Study (2016) (13)
Sustained HIV viral suppression following treatment interruption: an observational study. (2006) (13)
Racial disparities in the prevalence and control of hypertension among a cohort of HIV-infected patients in the southeastern United States (2018) (13)
HIV Resistance Testing in Clinical Practice: A QALY-fied Success (2001) (13)
Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia (2020) (12)
Anti – HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140 , a CCR 5 Monoclonal Antibody (2010) (12)
The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals (2017) (12)
Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications. (2011) (12)
Dermatologic manifestations of human immunodeficiency virus infection (1997) (12)
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals (2019) (11)
Physical Functioning Among Patients Aging With Human Immunodeficiency Virus (HIV) Versus HIV Uninfected: Feasibility of Using the Short Physical Performance Battery in Clinical Care of People Living With HIV Aged 50 or Older (2019) (11)
Case Report: Q Fever Endocarditis (1986) (11)
Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load. (2020) (11)
Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research (2016) (11)
Initiation of antiretroviral therapy: implications of recent findings. (2004) (11)
One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States (2018) (11)
Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction (2019) (11)
Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020 (2022) (11)
Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era. (2020) (10)
Direct-acting antivirals and chronic hepatitis C: towards elimination (2018) (10)
Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort (2019) (10)
Suitability of the PROMIS alcohol use short form for screening in a HIV clinical care setting. (2016) (10)
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects. (1992) (10)
Which policy to ADAP-T: waiting lists or waiting lines? (2006) (10)
Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States (2017) (10)
Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020 (2021) (10)
Antiretroviral pill count and clinical outcomes in treatment‐naïve patients with HIV infection (2018) (10)
Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio (2018) (10)
Opt-out testing: who can afford to take care of patients with newly diagnosed HIV infection? (2007) (10)
Health-Related Quality of Life in the Gender, Race, And Clinical Experience Trial (2011) (9)
Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. (2017) (9)
Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR. (2000) (9)
CD 4 : CD 8 Ratio and CD 8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy : The Antiretroviral Therapy Cohort Collaboration ( ARTCC ) (2017) (9)
Implementation of Computer-delivered Brief Alcohol Intervention in HIV Clinical Settings: Who Agrees to Participate? (2015) (9)
Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders* (2017) (9)
Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities (2017) (9)
Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies (2008) (9)
Intervention Mapping to develop a Social Cognitive Theory-based intervention for chronic pain tailored to individuals with HIV (2018) (9)
Patterns of self-reported adherence to ART in a prospective clinical cohort (1998) (9)
Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015. (2020) (9)
Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings (2015) (9)
Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic. (2014) (9)
Immunization costs and programmatic barriers at an urban HIV clinic. (2015) (9)
Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: Rationale and design of iENGAGE intervention trial. (2018) (9)
Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee (2017) (9)
P0887 : C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV (2015) (9)
Genetic architecture of cardiometabolic risks in people living with HIV (2020) (9)
Prioritizing CD4 Count Monitoring in Response to ART in Resource-Constrained Settings: A Retrospective Application of Prediction-Based Classification (2012) (8)
HIV Clinic Capacity and Medical Workforce Challenges: Results of a Survey of Ryan White Part C-funded Programs (2011) (8)
Evolving understanding of the immunopathogenesis of HIV. (1994) (8)
Timing of Antiretroviral Therapy Initiation and Risk of Cancer among Persons Living with HIV. (2020) (8)
Surgical determination of the site of crossing of jaw-opening reflex evoked by tooth pulp stimulation in the cat (1981) (8)
Drug and alcohol use among people living with HIV in care in the United States by geographic region (2021) (8)
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study (2021) (8)
Decreased Alcohol Consumption in an Implementation Study of Computerized Brief Intervention among HIV Patients in Clinical Care (2021) (8)
erratum: Antibody neutralization and escape by HIV-1 (2003) (8)
Mortality Among Persons Entering HIV Care Compared With the General U.S. Population (2021) (8)
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS). (2008) (8)
Factors Associated with Missed Psychiatry Visits in an Urban HIV Clinic (2015) (7)
HIV care at a crossroads: the emerging crisis in the US HIV epidemic. (2007) (7)
Effi cacy and safety of grazoprevir ( MK-5172 ) and elbasvir ( MK-8742 ) in patients with hepatitis C virus and HIV co-infection ( C-EDGE CO-INFECTION ) : a non-randomised , open-label trial (2015) (7)
Corrigendum to “Modeling sequence evolution in acute HIV-1 infection” [J. Theor. Biol. 261 (2009) 341–360] (2012) (7)
Itraconazole oral solution: pharmacokinetics and absorption. (1997) (7)
Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection. (2014) (7)
The role of toxicity-related regimen changes in the development of antiretroviral resistance. (2011) (7)
Dynamic Visual Display of Treatment Response in HIV-Infected Adults. (2015) (6)
Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. (1996) (6)
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. (2004) (6)
Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV. (2017) (6)
Safer in care: A pandemic-tested model of integrated HIV/OUD care (2021) (6)
Editorial commentary: Fixing a hole in the HIV safety net. (2015) (6)
A Prospective Cost-Consequence Analysis of Adding Lamivudine to Zidovudine-Containing Antiretroviral Treatment Regimens for HIV Infection in the US (2012) (6)
Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study. (2018) (6)
Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017. (2020) (6)
Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV (2018) (6)
Cost considerations in the current antiretroviral era (2016) (6)
Age at cancer diagnosis among persons with AIDS. (2011) (6)
1634. A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use (2018) (6)
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. (2008) (6)
Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naï ve Patients: 192 Week Results from STARTMRK (2011) (6)
Fructosamine and Hemoglobin A1c Correlations in HIV-Infected Adults in Routine Clinical Care: Impact of Anemia and Albumin Levels (2015) (6)
Short Communication: Viral Suppression Is Associated with Increased Likelihood of Colorectal Cancer Screening Among Persons Living with HIV/AIDS. (2015) (5)
P99 Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate (2015) (5)
The biological sciences section program at the 60th Annual Meeting of the Gerontological Society of America. (2005) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
CONCISE COMMUNICATIONS Decrease of Cytomegalovirus Replication in Human Immunodeficiency Virus Infected-Patients after Treatment with Highly Active Antiretroviral Therapy (1999) (5)
Factors Associated with Delayed Hepatitis B Viral Suppression on Tenofovir Among HBV-HIV Coinfected Patients in the CNICS Cohort (2014) (5)
Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice (2017) (5)
Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the US. (2019) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Faculty roundtable discussion. (1998) (5)
Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Question and answer session. (1998) (5)
A Plea for Justice for Jailed Medical Workers (2006) (5)
The experts speak. Burn-out among HIV care providers. Interview by Vicki Glaser. (2006) (4)
Association of Infection with Chronic Hepatitis C Virus and Myocardial Infarction in People Living with HIV in the United States. (2019) (4)
Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States. (2013) (4)
Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy (2016) (4)
Comprar The Sanford Guide To Hiv/Aids Therapy 2012 (Pocket Edition) 20ª Ed. | Michael S. Saag | 9781930808690 | Antimicrobial Therapy (2011) (4)
Chronic hepatitis B virus monoinfection at a university hospital in Zambia (2018) (4)
Letter in Response to the New SHEA Guideline for Healthcare Workers with Hepatitis B Virus, Hepatitis C Virus, and/or Human Immunodeficiency Virus (2010) (4)
HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy (2021) (4)
Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death (2020) (4)
The role of immunotherapy in the treatment of HIV. (2001) (4)
The PROSPER-HIV Study: A Research Protocol to Examine Relationships Among Physical Activity, Diet Intake, and Symptoms in Adults Living With HIV. (2019) (4)
Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes. (2013) (4)
Brief Report: Factors Associated With the Selection of Initial Antiretroviral Therapy From 2009 to 2012 (2017) (4)
Brief Report: Differences in Types of Myocardial Infarctions Among People Aging With HIV. (2021) (4)
What to do when zidovudine fails. (1994) (4)
The Relationship of Pain to Physical Function in Patients With HIV: An Underappreciated Phenomenon (SA517-B) (2013) (4)
Q fever endocarditis (1976) (3)
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210. (2019) (3)
P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study (2015) (3)
A 12-year retrospective evaluation of anal pre-cancerous lesions and cancer in people living with HIV-1 infection in the Southeastern U.S (2021) (3)
Roundtable. Who should be providing HIV care? (2006) (3)
Types of Stroke Among People Living With HIV in the United States. (2021) (3)
Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients. (2013) (3)
Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies (2020) (3)
Is It Time To Proactively Switch Successful Antiretroviral Therapy? Carefully Check Your SWATCH (2003) (3)
Erratum to: Migrating from a legacy fixed-format measure to CAT administration: calibrating the PHQ-9 to the PROMIS depression measures (2013) (3)
Indoleamine 2,3 dioxygenase, age, and immune activation in people living with HIV (2021) (3)
A mentor training workshop focused on fostering diversity engenders lasting impact on mentoring techniques: Results of a long-term evaluation (2021) (3)
Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness. (2020) (3)
The authors reply. (2014) (3)
Special section: COVID-19 among people living with HIV (2020) (2)
Obesity Affects the Association of Bioelectrical Impedance Phase Angle With Mortality in People Living With HIV. (2020) (2)
Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study (2020) (2)
Mortality after cancer diagnosis among HIV-infected individuals in the CFAR Network of Integrated Clinical Systems (CNICS) (2010) (2)
Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice. (2000) (2)
1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV (2020) (2)
Racial and ethnic disparities in COVID-19 disease incidence independent of comorbidities, among people with HIV in the US (2021) (2)
HIV 101: fundamentals of antiretroviral therapy. (2019) (2)
MINIREVIEW Azole Antifungal Agents: Emphasis on New Triazoles (2)
Decline in locomotor functions over time in HIV-infected patients. (2014) (2)
Editorial commentary. Viva no difference! (2012) (2)
What's All This Fuss I hear about Viral "Blips"? (2020) (2)
Brief Report: Insomnia and Risk of Myocardial Infarction Among People With HIV (2022) (2)
A Randomized Controlled Trial Protocol to Evaluate the Effectiveness of an Integrated Care Management Approach to Improve Adherence Among HIV-Infected Patients in Routine Clinical Care: Rationale and Design (2016) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Knowledge and self-reported use of universal precautions in a university teaching hospital. (1994) (2)
Marked variation in the susceptibility of HIV-1 to type 1 interferon inhibition during early, late and rebound infection (2019) (2)
The ghosts of Christmas past. How would those we've lost guide us today? (2011) (1)
Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to Eleven Years. (2020) (1)
HOST GENETIC FACTORS ASSOCIATED WITH CERVICAL HUMAN PAPILLOMAVIRUS CLEARANCE (2013) (1)
Correction: A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics (2010) (1)
When to start: as soon as possible (2012) (1)
Changes in lipidomic profile by anti-retroviral treatment regimen (2021) (1)
A 12-year retrospective evaluation of anal pre-cancerous lesions and cancer in people living with HIV-1 infection in the Southeastern U.S (2021) (1)
Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment. (2022) (1)
Antiretroviral therapy: select lessons from recent studies. (2003) (1)
Cumulative Viral Load Predicts All-Cause and AIDS-Related Mortality After Initiation of ART (2014) (1)
Track C Epidemiology and Prevention Science (2012) (1)
Case 36-2019: A 34-Year-Old Man with Dyspnea, Odynophagia, and Abdominal Pain. (2019) (1)
InVitro Activity ofPiperacillin, Ticarcillin, andMezlocillin Alone andinCombination withAminoglycosides against Pseudomonas aeruginosa (1986) (1)
The Human Immunodeficiency Virus (2002) (1)
Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART (2019) (1)
The impact of COVID-19 on mentoring early-career investigators (2021) (1)
Progression of Platelet Counts in Treatment Naïve HIV/HCV Co-Infection * (2013) (1)
Response : HIV and AIDS (1993) (1)
Class of antiretroviral drugs and anemia risk in the current treatment era (2019) (1)
Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort (2022) (1)
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018 (2020) (1)
115. Opioid Continuum of Care for Persons Living with HIV: The First 8 Months (2020) (1)
Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. (2018) (1)
Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings (2017) (1)
Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States (2022) (1)
Saag changing priorities in the HAART era Gastrointestinal complications of HIV infection : (2008) (1)
Evolution of HIV-1 Drug Resistance after Virological Failure of First-line Antiretroviral Therapy in Lusaka, Zambia (2019) (1)
(194) Qualitative investigation of a brief chronic pain screening tool in HIV-infected patients (2014) (1)
Clinical Investigation of HIV Disease (1994) (1)
Risk factors for atrial fibrillation in a multi-center US clinical cohort of people with HIV infection. (2022) (1)
P98 Design of a phase III trial of cryptococcal meningitis in AIDS patients (1995) (1)
Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment-Reply. (2018) (1)
Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries (2015) (1)
Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science (2022) (1)
HIV Viral Suppression Trends (2019) (1)
Anal cancer incidence in MSM with HIV (2021) (0)
Persistent plasma viremia in acute and early chronic HIV-1 infection Implications for natural history and pathogenesis (1993) (0)
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour. (1996) (0)
Incorrect Data in Figures. (2018) (0)
1555Factors Associated with the Selection of Initial Antiretroviral Therapy: Real-world Channeling (2014) (0)
Question-and-Answer Session (2010) (0)
An approach to antiretroviral treatment of HIV disease. The situation: an overview. (1995) (0)
Ryan White CARE Act reauthorization: we need help. (2006) (0)
Integration of Clinical Data to Support HIV Research (2007) (0)
Hepatitis C eradication: Is it possible? (2016) (0)
Comprar The Sanford Guide To Antimicrobial Therapy 2012 (Library Edition) 42nd Ed. | Michael S. Saag | 9781930808720 | Antimicrobial Therapy (2012) (0)
Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3) (2011) (0)
Strategies for long-term patient management. (1998) (0)
Mezlocillin Alone and in Combination with Aminoglycosides against Pseudomonas aeruginosa (0)
325 FACTORS ASSOCIATED WITH SURVIVAL IN HIV PATIENTS WITH PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY. (2006) (0)
Trends in Cancer Incidence Rates among HIV-Infected Patients (2010) (0)
CD4:CD8 ratio and CD8 count as prognostic markers for mortality in HIV-positive patients on ART (2017) (0)
TUPDC0103: Gonorrhea infections diagnosed among persons living with HIV: cross matching surveillance registries to identify potential opportunities for integrated partner services-New York City, Washington D.C., Miami/Dade County and Arizona (2012) (0)
AIDS new editor announcement. (2020) (0)
Copd And The Risk For Myocardial Infarction By Type In People With Hiv. (2022) (0)
Board – – – – — — – — — — — — — — IAS – USA Board of Directors — — — — – — — — — — (2018) (0)
Cases From the Field Epidermodysplasia Verruciformis in an HIV-Infected Man : A Case Report and Review of the Literature 173 (2013) (0)
Association of time-updated adherence to ART on rates of AIDS/death: a cross-cohort analysis (2013) (0)
Gender Differences in Discontinuation/Change of Hiv Therapy (2006) (0)
Distribution of age at death and effects of immunosuppression and ART duration vary according to cause of death in HIV-1 positive people (2012) (0)
Discussion: What are the optimal regimens for postexposure chemoprophylaxis? (1997) (0)
Clinical approach to the choice of antimicrobial therapy, case no. 22: recurrent furunculosis. (1980) (0)
Hot Topics in Infectious Diseases and HIV Medicine (2007) (0)
High alcohol use is associated with non-AIDS-related mortality in the ART-CC (2015) (0)
Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV. (2023) (0)
Starting cART in antiretroviral-naïve HIV-1–infected patients presenting with cryptococcal meningitis (2014) (0)
Early antiretroviral therapy not associated with higher cryptococcal meningitis mortality in people with HIV in high-income countries: an international collaborative cohort study. (2023) (0)
Association between chronic hepatitis C virus infection and myocardial infarction in people living with HIV in the United States (2018) (0)
Efficacy and Safety Results of TMC114/r at 24 Weeks in Treatment-Experienced Patients: POWER 3 (2006) (0)
Correction to: Genetic architecture of cardiometabolic risks in people living with HIV (2021) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Development of COVID-19 Vaccines-An Unanticipated Moon Shot Achieved at Warp Speed. (2023) (0)
High Efficacy of Grazoprevir/Elbasvir Among HCV GT1, GT4, Or GT6 Infected Patients with HIV Co-Infection (2015) (0)
IAS-USA Board of Directors (2011) (0)
HIV Symptom Clusters Are Similar Using the Dimensions of Symptom Occurrence and Distress. (2022) (0)
AIDS Therapy e-dition, 3rd Edition (2008) (0)
Cumulative incidence of and risk factors for changes to first ART regimen and death prior to a change: the Antiretroviral Therapy Cohort Collaboration (ART-CC) (2012) (0)
Characteristics Associated with COPD in People Living with HIV in the Current Antiretroviral Therapy (ART) Era (2019) (0)
Tuberculosis Increases Long-Term Risk of Mortality due to non-AIDS defining events (NADEs) among HIV-infected persons on Antiretroviral Therapy (ART) (2015) (0)
HIV post-treatment controllers have distinct immunological and virological features. (2023) (0)
Associations of risk group, gender and age with specific causes of death in the ART-CC (2012) (0)
Abstract 26: Assessing and Refining Cardiovascular Disease Risk Estimation Among Patients with Human Immunodeficiency Virus: Center for Acquired Immunodeficiency Syndrome Research Network of Integrated Clinical Systems (2016) (0)
Abstract 588, 16th Conference on Retroviruses and Opportunistic Infections, Montreal, USA (2009) (0)
P65 The impact of early closure of a clinical trial on a related study (1996) (0)
Initiation of Antiretroviral Therapy : Current Controversies in When and with What to Start (2012) (0)
Faculty Roundtable Discussion (1998) (0)
Editor's comment. (2020) (0)
Erratum: Treatment with Recombinant Growth Hormone Is Associated with Modest Improvement in CD4 Lymphocyte Reconstitution in HIV-Infected Persons on Antiretroviral Therapy: Results of ACTG A5174 (AIDS Research and Human Retroviruses (2010) 26 (425-432)) (2010) (0)
Response : Effect of Platelet-Associated Virus on Assays of HIV-1 in Plasma (1993) (0)
Antiretroviral Drug Recommendations for HIV Treatment and Prevention-Reply. (2021) (0)
Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV (2022) (0)
Déjà vu all over again. (2019) (0)
Comprar AIDS Therapy e-dition | Michael S. Saag | 9780443067525 | Churchill Livingstone (2007) (0)
Comprar The Sanford Guide To Antimicrobial Therapy 2012 (Pocket Edition) 42nd Ed. | Michael S. Saag | 9781930808706 | Antimicrobial Therapy (2012) (0)
(499) Evaluation of a pilot physical therapy program for HIV-infected patients with chronic pain (2014) (0)
HIV Infection - Screening, Diagnosis, and Treatment. Reply. (2021) (0)
Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee (2017) (0)
Ryan White CARE Act reauthorization: we need help. (2006) (0)
Causes of Death in Patients Treated with ART, 1996 to 2006: Collaborative Analysis of 13 Cohort Studies (2009) (0)
Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV (2023) (0)
Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States. (2022) (0)
Hepatitis C and B Viruses: The New Opportunists in HIV Infection 78 (2006) (0)
Editorial 44.pmd (2005) (0)
Discussion: Zidovudine toxicity in uninfected healthcare workers (1997) (0)
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
Information , Inspiration and Advocacy for People Living with HIV / AIDS (2004) (0)
Developing COVID-19 vaccine policy in increments (2021) (0)
In Vitro Effect of Ofloxacin Alone and in Combination with Ceftazidime or Gentamicin against P. aeruginosa (1993) (0)
Heightened resistance to type 1 interferons characterizes HIV-1 at transmission and following analytical treatment interruption (2020) (0)
IDSA Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA Module: Hepatitis C 2015 (2016) (0)
17th International Workshop on HIV Observational Databases, Cavtat, Croatia (2013) (0)
Antiretrovirals for HIV nephropathy? (1999) (0)
Editorial: The Changing Face of AIDS Research and Human Retroviruses: A New Forum to Display Your ART-Work (1998) (0)
Title: Impact of antiretroviral therapy on liver fibrosis among HIV-infected adults with and without HBV coinfection in Zambia (2017) (0)
Comprar The Sanford Guide To Antimicrobial Therapy 2012 (Spiral Edition) 42nd Ed. | David N. Gilbert | 9781930808713 | Antimicrobial Therapy (2012) (0)
Abstract WMP55: HIV Viral Load and Stroke Risk (2020) (0)
Influence of Age on Outcomes in HIV-Infected Adults Initiating Tenofovir Alafenamide Fumarate (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F/TAF versus E/C/F/TDF) (2015) (0)
639. Indoleamine 2,3 Dioxygenase, Age, and Chronic Immune Activation in HIV Patients (2018) (0)
Abstract LB-160: Incidence of non-AIDS-defining cancers over time in the post-ART era (2018) (0)
Development of frail RISC-HIV: a risk score for predicting frailty risk in the short-term for care of people with HIV. (2023) (0)
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
Evolving trends in causes of death among treated HIV-positive individuals (2015) (0)
In Memorium: William Ernest Dismukes 1939-2017. (2017) (0)
HIV and AIDS (2007) (0)
HIV/AIDS: the only thing constant... (2009) (0)
Approach to the use of antimicrobial combinations. (1985) (0)
Outcomes of Abacavir and Efavirenz based HAART: Comparison of ACTG 5095 Trial Results with Observational Cohort Studies (2008) (0)
Reply to Dal Maso et al (2005) (0)
A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. (2017) (0)
Current Antiretroviral Treatment Among People With Hiv In The Us: Findings From The Cnics Cohort. (2022) (0)
Impact of glycan positioning on HIV-1 Env glycan shield density, function, and antibody recognition (2020) (0)
Anal cancer incidence in men with HIV who have sex with men: are black men at higher risk? (2021) (0)
Validity Properties of a Self-reported Modified Frailty Phenotype Among People With HIV in Clinical Care in the United States (2023) (0)
Effect of antiretroviral therapy on plasma HIV RNA. (1995) (0)
Associations between female birth sex and risk of chronic kidney disease development among people with HIV in the USA: A longitudinal, multicentre, cohort study (2022) (0)
Opportunistic pricing: a new scourge, a new call for action. (1998) (0)

This paper list is powered by the following services:

Other Resources About Michael Saag

en.wikipedia.org

What Schools Are Affiliated With Michael Saag?

Michael Saag is affiliated with the following schools: